XBiotech
XBIT
38 hedge funds and large institutions have $8.61M invested in XBiotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
0.75% less ownership
Funds ownership: 8.79% → 8.03% (-0.75%)
5% less funds holding
Funds holding: 40 → 38 (-2)
8% less capital invested
Capital invested by funds: $9.39M → $8.61M (-$779K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $37K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$142K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32.2K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$12K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4K |
| 5 |
BlackRock
New York
|
+$3.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$481K |
| 2 |
Man Group
London,
United Kingdom
|
-$183K |
| 3 |
Renaissance Technologies
New York
|
-$182K |
| 4 |
D.E. Shaw & Co
New York
|
-$52.8K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$50K |
XBIT Hedge Fund Activity: Q1 2023 in Review
38 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2023, worth a combined $8.61M — down 8.3% from $9.39M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of XBIT and 4 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $142K. The largest seller was Oasis Management Company, exiting entirely with an estimated $481K sold.
- 38 institutional investors held XBiotech (XBIT) as of Q1 2023, down from 40 in Q4 2022.
- Funds reported $8.61M of XBiotech stock for Q1 2023, down 8.3% quarter-over-quarter.
- 4 funds opened new XBiotech positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest XBiotech buyer in Q1 2023 was Susquehanna International Group, an estimated $142K added.
- The largest XBiotech seller in Q1 2023 was Oasis Management Company, an estimated $481K sold.
Based on aggregated 13F filings for Q1 2023.